Genfit SA (GNFT) Price & Analysis

Compare

265 Followers

GNFT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.55 - $6.42

Previous CloseN/A

Volume1.39K

Average Volume (3M)3.53K

Market Cap

$199.89M

Enterprise Value$164.61M

Total Cash (Recent Filing)$61.65M

Total Debt (Recent Filing)$67.80M

Price to Earnings (P/E)115.1

Beta0.64

Next Earnings

Sep 22, 2025

EPS Estimate

2.48

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.64

Shares Outstanding50,002,834

10 Day Avg. Volume3,482

30 Day Avg. Volume3,526

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.82

Enterprise Value/Revenue2.11

Enterprise Value/Gross Profit2.13

Enterprise Value/Ebitda6.68

Forecast

1Y Price Target

$4.00

Price Target Upside5.54% Upside

Rating ConsensusHold

Number of Analyst Covering0

Bulls Say, Bears Say

Bulls Say

Clinical TrialsPreliminary safety data from a study with GNS561 and trametinib in patients with KRAS-mutated cholangiocarcinoma supported the study's continuation, reflecting positive developments in their clinical trials.

Financial StabilityGENFIT entered into a royalty financing agreement with HealthCare Royalty (HCRx) for up to €185M in total funding, providing financial stability and resources for future projects.

Pipeline DevelopmentMultiple clinical catalysts later in 2025 could boost confidence in the rare liver disease pipeline.

Research And DevelopmentGENFIT announced a list of its 2025 milestones that includes up to four clinical data readouts from its Acute on-Chronic Liver Failure (ACLF) programs, indicating progress in their research and development efforts.

Bears Say

Debt ManagementPlans to eliminate outstanding convertible debt should provide further capital flexibility for the company moving forward.

Patient EnrollmentA protocol amendment to improve the logistics of enrolling ACLF patients has been implemented to accelerate patient enrollment, indicating proactive steps to enhance clinical trial efficiency.

Genfit SA News

Genfit SA’s New Study on G1090N: A Potential Game-Changer?

Genfit SA (($GNFTF)), Genfit (($GNFT)) announced an update on their ongoing clinical study. Genfit SA (GNFTF) has announced...

11h ago

GNFT

GENFIT Releases Half-Year Liquidity Contract Report

Genfit SA ( ($GNFT) ) has shared an announcement. On July 8, 2025, GENFIT announced the half-year report...

1M ago

GNFT

GENFIT Shareholders Approve Key Resolutions at June 2025 Meeting

The latest announcement is out from Genfit SA ( ($GNFT) ). On June 17, 2025, GENFIT announced the...

2M ago

GNFT

GENFIT Reports Strong Q1 Financials and Leadership Change

Genfit SA ( ($GNFT) ) has shared an announcement. On May 22, 2025, GENFIT reported its financial results...

3M ago

GNFT

GENFIT Secures €26.5 Million Milestone with Ipsen’s Iqirvo® Approval in Italy

Genfit SA ( ($GNFT) ) has shared an update. On May 20, 2025, GENFIT announced it will receive...

3M ago

GNFT

Genfit to receive EUR 26.5M Iqirvo milestone payment from Ipsen agreement

Genfit (GNFT) announced that Ipsen’s Iqirvo has been granted pricing and reimbursement in Italy for Primary Biliary Cholangitis....

3M ago

GNFT

GENFIT Publishes 2025 Extra-Financial Performance Report

The latest update is out from Genfit SA ( ($GNFT) ). On May 14, 2025, GENFIT announced the...

3M ago

GNFT

GENFIT Announces Details for June 2025 Shareholders’ Meeting

Genfit SA ( ($GNFT) ) has shared an announcement. On May 7, 2025, GENFIT announced the details of...

3M ago

GNFT

GENFIT Highlights ACLF Research at EASL Congress 2025

Genfit SA ( ($GNFT) ) just unveiled an announcement. On May 5, 2025, GENFIT announced its participation in...

3M ago

GNFT

GENFIT Releases 2024 Annual Reports, Enhancing Transparency

Genfit SA ( ($GNFT) ) just unveiled an announcement. On April 29, 2025, GENFIT announced the publication of...

3M ago

GNFT

GENFIT’s Elafibranor Shows Promising Phase 2 Results in PSC

Genfit SA ( ($GNFT) ) has provided an announcement. GENFIT announced that Ipsen will present positive Phase 2...

3M ago

GNFT

Genfit announces final terms for dual proposal to 2025 Oceanes holders

Genfit (GNFT) announced the final terms of the 2025 Oceanes repurchase proposal and the consent fee that would...

6M ago

GNFT

Genfit announces positive CHMP opinion for Ipsen’s Iqirvo

GENFIT (GNFT) announced the positive opinion issued by the Committee for Medicinal Products for Human Use of the...

1y ago

GNFT

Genfit: New EASL-EASD-EASO guidelines include NIS2+

Genfit announced the inclusion of NIS2 as a key tool for detecting at-risk MASH1 in the European Clinical...

1y ago

GNFT

GNFT FAQ

What was Genfit’s price range in the past 12 months?

Genfit lowest stock price was $2.55 and its highest was $6.42 in the past 12 months.

What is Genfit’s market cap?

Genfit’s market cap is $199.89M.

When is Genfit’s upcoming earnings report date?

Genfit’s upcoming earnings report date is Sep 22, 2025 which is in 45 days.

How were Genfit’s earnings last quarter?

Genfit released its earnings results on Apr 24, 2025. The company reported -$0.637 earnings per share for the quarter, missing the consensus estimate of -$0.256 by -$0.381.

Is Genfit overvalued?

According to Wall Street analysts Genfit’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Genfit pay dividends?

Genfit does not currently pay dividends.

What is Genfit’s EPS estimate?

Genfit’s EPS estimate is 2.48.

How many shares outstanding does Genfit have?

Genfit has 50,002,834 shares outstanding.

What happened to Genfit’s price movement after its last earnings report?

Genfit reported an EPS of -$0.637 in its last earnings report, missing expectations of -$0.256. Following the earnings report the stock price went down -0.817%.

Which hedge fund is a major shareholder of Genfit?

Currently, no hedge funds are holding shares in GNFT

Genfit SA Stock Smart Score

Underperform

Fundamentals

Return on Equity

2.17%

Trailing 12-Months

Asset Growth

-18.30%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Genfit

Genfit SA (GNFT) is a biopharmaceutical company headquartered in France, focused on the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver-related diseases. The company's core products and services revolve around developing drug candidates for non-alcoholic steatohepatitis (NASH), fibrotic diseases, and other liver disorders. Genfit aims to address significant unmet medical needs and improve patient outcomes through its research and development efforts.